1. 3/24/15, 2:26 PMOASIS
Page 1 of 6http://www.abstractsonline.com/Plan/SSResults.aspx
> Return to AACR Annual Meeting
Results matching the search 1-16 of 16
Presentation Search Results
Select/Clear All Presentations per Page 25 Add Checked Selections to My Itinerary
Presentation Session
Sat, Apr 18, 5:30 - 5:45 PM
Using Twitter and LinkedIn to
lead and follow your field
Wafik S. El-Deiry. Fox Chase
Cancer Center, Philadelphia, PA
Professional Advancement
Session
PAS11. Social Media for Scientists
Sat, Apr 18, 5:30 - 6:30 PM
Sun, Apr 19, 1:00 - 5:00 PM
382/21 - Identification and
characterization of circulating
tumor cells with multiplexed
Quantum Dot conjugated
antibodies
Lanlan Zhou, Elizabeth M.
Matthew, David T. Dicker, Wafik S.
El-Deiry. Laboratory of
Translational Oncology and
Experimental Cancer Therapeutics,
Department of Medical Oncology
and Molecular Therapeutics
Program, Fox Chase Cancer
Center, Philadelphia, PA
Poster Session
PO.TB04.02. Circulating Tumor
Cells and Disseminated Tumor
Cells
Sun, Apr 19, 1:00 - 5:00 PM
Sun, Apr 19, 1:00 - 5:00 PM
674/18 - Early integrated
stress response induction of
ATF4 is required for the
anticancer effects of the dual
Akt/ERK inhibitor and TRAIL
pathway inducer
ONC201/TIC10
Christina Leah Kline1, Pieter van
den Heuvel2, Joshua E. Allen3,
David T. Dicker1, Wafik S. El-
Deiry1. 1Laboratory of
Translational Oncology and
Experimental Cancer Therapeutics,
Department of Medical Oncology
and Molecular Therapeutics
Program, Fox Chase Cancer
Center, Philadelphia, PA; 2Penn
State Hershey Cancer Institute,
Hershey, PA; 3Oncoceutics, Inc.,
Philadelphia, PA
Poster Session
PO.ET02.01. Signal Transduction
Inhibitors
Sun, Apr 19, 1:00 - 5:00 PM
Mon, Apr 20, 8:00 AM - 12:00
PM
Elizabeth M. Matthew1, Lanlan
Zhou1, Namrata Vijayvergia2,
Poster Session
PO.CL11.01. Circulating Tumor
2. 3/24/15, 2:26 PMOASIS
Page 2 of 6http://www.abstractsonline.com/Plan/SSResults.aspx
1600/21 - A multiplexed
marker-based algorithm for
diagnosis of carcinoma of
unknown primary using
circulating tumor cells
David T. Dicker1, Karen S.
Gustafson2, Harry S. Cooper2, Eric
A. Ross2, Bora Lim3, Ramdane
Harouaka4, Si-Yang Zheng4,
Nicholas E. Lamparella5, Joseph J.
Drabick5, Cristina I. Truica5,
Zhaohai Yang5, Wafik S. El-Deiry1.
1Laboratory of Translational
Oncology and Experimental Cancer
Therapeutics, Department of
Medical Oncology and Molecular
Therapeutics Program, Fox Chase
Cancer Center, Philadelphia, PA;
2Fox Chase Cancer Center,
Philadelphia, PA; 3The University
of Texas MD Anderson Cancer
Center, Houston, TX; 4Department
of Biomedical Engineering, Penn
State University, University Park,
PA; 5Penn State Hershey Medical
Center, Hershey, PA
Cells
Mon, Apr 20, 8:00 AM - 12:00 PM
Mon, Apr 20, 8:00 AM - 12:00
PM
1215/4 - Small molecule
Prodigiosin-mediated p53
pathway restoration and
inhibition of self-renewal in
colorectal cancer involves c-
Jun-mediated ΔNp73 inhibition
and p73 activation.
Varun Vijay Prabhu, Shengliang
Zhang, Bo Hong, Joshua E. Allen,
Amriti Lulla, David T. Dicker, Wafik
S. El-Deiry. Laboratory of
Translational Oncology and
Experimental Cancer Therapeutics,
Department of Medical Oncology
and Molecular Therapeutics
Program, Fox Chase Cancer
Center, Philadelphia, PA
Poster Session
PO.MCB04.03. Nuclear Tumor
Suppressors
Mon, Apr 20, 8:00 AM - 12:00 PM
Mon, Apr 20, 1:00 - 5:00 PM
2527/9 - The drug
combination sorafenib and
quinacrine targets the
expression of Mcl-1 - an anti-
apoptotic protein and
candidate prognostic factor in
Anaplastic Thyroid Cancer
(ATC)
Junaid Abdulghani1, Jean-Nicholas
Gallant1, Prashanth Gokare2,
Timothy Cooper3, Tiffany
Whitcomb3, Jiangang Liao4, Jing
Liu5, David Goldenberg6, Niklas K.
Finnberg2, Wafik S. El-Deiry2.
1Penn State Hershey Cancer
Institute, Hershey, PA;
2Laboratory of Translational
Oncology and Experimental Cancer
Therapeutics, Department of
Medical Oncology and Molecular
Therapeutics Program, Fox Chase
Cancer Center, Philadelphia, PA;
3Department of Comparative
Medicine, Penn State Hershey
Medical Center, Hershey, PA;
4Department of Public Health
Poster Session
PO.ET01.02. Combination
Chemotherapy 1
Mon, Apr 20, 1:00 - 5:00 PM
3. 3/24/15, 2:26 PMOASIS
Page 3 of 6http://www.abstractsonline.com/Plan/SSResults.aspx
Sciences, Penn State Hershey
Medical Center, Hershey, PA;
5Department of Pathology and
Laboratory Medicine, University of
Texas Health Science Center at
Houston Medical School, Houston,
TX; 6Department of Surgery, Penn
State Hershey Medical Center,
Hershey, PA
Mon, Apr 20, 1:00 - 5:00 PM
2640/11 - Small molecule
compound NCI-8 induces
ERK2-dependent mutant-p53
protein degradation
Shengliang Zhang, Lanlan Zhou,
David T. Dicker, Wafik S. EL-Deiry.
Laboratory of Translational
Oncology and Experimental Cancer
Therapeutics, Department of
Medical Oncology and Molecular
Therapeutics Program, Fox Chase
Cancer Center, Philadelphia, PA
Poster Session
PO.ET07.02. Oncogenes, Tumor
Suppressor Genes, and Gene
Products as Targets for Therapy
Mon, Apr 20, 1:00 - 5:00 PM
Mon, Apr 20, 1:00 - 5:00 PM
2643/14 - Small molecule
identification for the
restoration of p53 pathway
through p73 and by
degradation of mutant p53
Liz J. Hernandez Borrero,
Shengliang Zhao, David T. Dicker,
Wafik El-Deiry. Laboratory of
Translational Oncology and
Experimental Cancer Therapeutics,
Department of Medical Oncology
and Molecular Therapeutics
Program, Fox Chase Cancer
Center, Philadelphia, PA
Poster Session
PO.ET07.02. Oncogenes, Tumor
Suppressor Genes, and Gene
Products as Targets for Therapy
Mon, Apr 20, 1:00 - 5:00 PM
Tue, Apr 21, 8:00 AM - 12:00
PM
3486/9 - Synergistic effect of
quinacrine in combination with
decitabine for the treatment of
acute myeloid leukemia cells in
vitro: implication for treatment
of AML in the elderly
Wenge Wang1, David T. Dicker2,
David F. Claxton1, Hong-Gang
Wang3, Wafik S. El-Deiry2.
1Hematology/Oncology, Penn
State Hershey Medical Center,
Cancer Institute, Hershey, PA;
2Department of Medical Oncology
and Molecular Therapeutics
Program, Fox Chase Cancer
Center, Philadelphia, PA;
3Department of Pediatrics, Penn
State College of Medicne, Hershey,
PA
Poster Session
PO.ET01.03. Combination
Chemotherapy 2
Tue, Apr 21, 8:00 AM - 12:00 PM
Tue, Apr 21, 8:00 AM - 12:00
PM
2926/13 - DR5-targeting
sensitizes Lgr5+ stem cells to
p53 and Chk2-dependent
chemotherapy-induced cell
death and produces dose-
limiting gastrointestinal
toxicity (GIT)
Niklas K. Finnberg1, Prashanth
Gokare1, Arunasalam Navaraj2,
Krystle A. Lang Kuhs3, George
Cerniglia4, Hideo Yagita5,
Kazuyoshi Takeda5, Noboru
Motoyama6, Wafik S. El-Deiry1.
1Laboratory of Translational
Oncology and Experimental Cancer
Therapeutics, Department of
Medical Oncology and Molecular
Therapeutics Program,, Fox Chase
Poster Session
PO.MCB02.02. Cell Death
Therapies 1
Tue, Apr 21, 8:00 AM - 12:00 PM
4. 3/24/15, 2:26 PMOASIS
Page 4 of 6http://www.abstractsonline.com/Plan/SSResults.aspx
Cancer Center, Philadelphia, PA;
2Penn State Hershey Cancer
Institute, Hershey, PA; 3Infections
and Immunoepidemiology Branch,
Division of Cancer Epidemiology
and Infections/National Cancer
Institute, Bethesda, MD;
4Department of Radiation
Oncology, School of Medicine,
University of Pennsylvania,
Philadelphia, PA; 5Department of
Immunology, Juntendo University
School of Medicine, Tokyo, Japan;
6Department of Cognitive Brain
Sciences, Research Institute,
National Center for Geriatrics and
Gerontology, Aichi, Japan
Tue, Apr 21, 8:00 AM - 12:00
PM
2942/29 - TRAIL pathway
inducer ONC201/TIC10 primes
multiple myeloma cells (MM)
for apoptosis by
downregulating X-linked
inhibitor of apoptosis
Christina Leah Kline1, Amriti R.
Lulla1, David Dicker1, Joshua E.
Allen2, Wafik El-Deiry1.
1Laboratory of Translational
Oncology and Experimental Cancer
Therapeutics, Department of
Medical Oncology and Molecular
Therapeutics Program, Fox Chase
Cancer Center, Philadelphia, PA;
2Oncoceutics, Inc., Philadelphia,
PA
Poster Session
PO.MCB02.02. Cell Death
Therapies 1
Tue, Apr 21, 8:00 AM - 12:00 PM
Tue, Apr 21, 1:00 - 5:00 PM
4475/2 - In vitro efficacy
profiling of ONC201 in cancer
cells reveals sensitivity pattern
that is consistent with ER
stress response
Joshua E. Allen1, Jo Ishizawa2,
Wafik S. El-Deiry3, Michael
Andreeff2, Mathew Garnett4, Cyril
Benes5. 1Oncoceutics, Philadephia,
PA; 2MD Anderson, Houston, TX;
3Fox Chase Cancer Center,
Philadephia, PA; 4Wellcome Trust
Sanger Institute, Cambridge,
United Kingdom; 5Massachusetts
General Hospital, Boston, MA
Poster Session
PO.ET06.10. Novel Targets 2
Tue, Apr 21, 1:00 - 5:00 PM
Tue, Apr 21, 1:00 - 5:00 PM
4479/6 - ONC201 is non-toxic
at efficacious doses in vitro
and in vivo
Joshua E. Allen1, Wafik S. El-
Deiry2. 1Oncoceutics, Philadelphia,
PA; 2Fox Chase Cancer Center,
Philadelphia, PA
Poster Session
PO.ET06.10. Novel Targets 2
Tue, Apr 21, 1:00 - 5:00 PM
Tue, Apr 21, 1:00 - 5:00 PM
4499/26 - Cytotoxicity,
biochemical activity, and
structural analysis of ONC201
and comparisons to a
biologically inactive isomer
Jessica Wagner1, Christina Leah
Kline1, Richard S. Pottorf2,
Bhaskara Rao Nallaganchu2, Gary
L. Olson2, David T. Dicker1, Joshua
E. Allen3, Wafik S. El-Deiry1.
Poster Session
PO.ET06.10. Novel Targets 2
Tue, Apr 21, 1:00 - 5:00 PM
